Citadel Advisors’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-11,607
| Closed | -$20.1K | – | 6864 |
|
|
2023
Q1 | $20.1K | Buy |
+11,607
| New | +$20.1K | ﹤0.01% | 5394 |
|
|
2022
Q3 | – | Sell |
-7,152
| Closed | -$33K | – | 7248 |
|
|
2022
Q2 | $33K | Buy |
7,152
+6,649
| +1,322% | +$30.7K | ﹤0.01% | 5614 |
|
|
2022
Q1 | $5K | Sell |
503
-352
| -41% | -$3.5K | ﹤0.01% | 6246 |
|
|
2021
Q4 | $13K | Sell |
855
-2,020
| -70% | -$30.7K | ﹤0.01% | 6350 |
|
|
2021
Q3 | $86K | Buy |
2,875
+1,426
| +98% | +$42.7K | ﹤0.01% | 5943 |
|
|
2021
Q2 | $49K | Sell |
1,449
-2,681
| -65% | -$90.7K | ﹤0.01% | 6209 |
|
|
2021
Q1 | $171K | Buy |
4,130
+3,373
| +446% | +$140K | ﹤0.01% | 5533 |
|
|
2020
Q4 | $46K | Buy |
757
+638
| +536% | +$38.8K | ﹤0.01% | 4864 |
|
|
2020
Q3 | $16K | Sell |
119
-899
| -88% | -$121K | ﹤0.01% | 4553 |
|
|
2020
Q2 | $172K | Buy |
1,018
+514
| +102% | +$86.8K | ﹤0.01% | 4118 |
|
|
2020
Q1 | $72K | Buy |
+504
| New | +$72K | ﹤0.01% | 4459 |
|
|
2019
Q4 | – | Sell |
-85
| Closed | -$42K | – | 5351 |
|
|
2019
Q3 | $42K | Sell |
85
-32
| -27% | -$15.8K | ﹤0.01% | 4388 |
|
|
2019
Q2 | $71K | Buy |
117
+44
| +60% | +$26.7K | ﹤0.01% | 4306 |
|
|
2019
Q1 | $45K | Buy |
73
+12
| +20% | +$7.4K | ﹤0.01% | 4261 |
|
|
2018
Q4 | $22K | Sell |
61
-96
| -61% | -$34.6K | ﹤0.01% | 4250 |
|
|
2018
Q3 | $106K | Buy |
157
+3
| +2% | +$2.03K | ﹤0.01% | 3891 |
|
|
2018
Q2 | $134K | Buy |
154
+110
| +250% | +$95.7K | ﹤0.01% | 3777 |
|
|
2018
Q1 | $56K | Buy |
+44
| New | +$56K | ﹤0.01% | 3734 |
|